SCHEMBL8301655

SCHEMBL8301655

COc1ccc2c(C)cc(N)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.56
NCF1 P14598 1/20 0.53
ACHE P22303 1/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 2/20 0.52
TSHR P16473 1/20 0.52
HBB P68871 1/20 0.52
HSD17B10 Q99714 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
NOS1 P29475 5/20 0.50
NOS3 P29474 4/20 0.50
NOS2 P35228 2/20 0.50
MPO P05164 1/20 0.49
NPSR1 Q6W5P4 2/20 0.48
MAPT P10636 1/20 0.48
APP P05067 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11350348 0.83 ALDH1A1 (0.59) NCF1ACHEKDM4EALDH1A1HPGD
SCHEMBL24009010 0.82 POLB (0.58) ACHEKDM4EALDH1A1HPGDTSHR
SCHEMBL5033285 0.81 NCF1 (0.51) NCF1ACHEKDM4EALDH1A1CYP1A2
SCHEMBL1166339 0.81 NCF1 (0.51) NCF1ACHEKDM4EALDH1A1CYP1A2
SCHEMBL8342226 0.80 NCF1 (0.50) NCF1ACHEKDM4EALDH1A1HPGD
SCHEMBL5427929 0.79 KDM4E (0.52) ACHEKDM4EALDH1A1HPGDTSHR
SCHEMBL5433758 0.79 KDM4E (0.56) ACHEKDM4EALDH1A1HPGDTSHR
SCHEMBL13293273 0.79 NCF1 (0.49) BACE1NCF1ACHEKDM4EALDH1A1
SCHEMBL11354583 0.76 NCF1 (0.46) NCF1ACHEKDM4EALDH1A1NOS1
SCHEMBL14819968 0.76 DHFR (0.52) NCF1ACHEKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116169-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-09 US disclosed
WO-2005035525-A2 2-AMIDO-4-ARYLOXY-1-CARBONYLPYRROLIDINE DERIVATIVES AS INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116169-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE SERPINB1, PRSS1, SPINT2 BACE1 280/4885NCF1 869/4885ACHE 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.